IN THE CLAIMS.

1. (Previously amended) A medical article, comprising an implantable substrate having a coating deposited on the substrate, the coating comprising a polymer, the polymer being a product of co-polycondensation of a diketene acetal and a diol,

wherein the diol comprises aliphatic, cycloaliphatic, aromatic, or organosilicon diols or combinations thereof,

wherein the aliphatic diol comprises alkylene glycols, poly- or oligoalkylene glycols, or mixtures thereof, and

wherein the alkylene glycols are selected from the group consisting of ethylene glycol, 1,2-propylene glycol, 1,4-butanediol, 1,5-pentanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, 1,12-dodecanediol, 1,13-tridecanediol, 1,14-tetradecanediol, 1,15-pentadecanediol, 1,16-hexadecanediol, 1,3-propylene glycol, butane-1,3-diol, pentane-2,4-diol, hexane-2,5-diol, and mixtures thereof.

- 2. (Original) The article of Claim 1, wherein the implantable substrate is a stent.
- 3. (Currently amended) The article of Claim 1, wherein the diketene acetal is selected from a group of compounds having formulae (I) or (II):

$$R \longrightarrow CH \longrightarrow C \longrightarrow CH_{2} \longrightarrow CH_{2} \longrightarrow CH \longrightarrow R_{1}$$

$$(I)$$

$$R_{1} \longrightarrow CH \longrightarrow C \longrightarrow CH_{2} \longrightarrow CH_{2} \longrightarrow CH \longrightarrow R_{2}$$

$$(II)$$

$$R_{1} \longrightarrow CH \longrightarrow C \longrightarrow CH \longrightarrow R_{2} \longrightarrow CH \longrightarrow R_{2}$$

$$(II)$$

$$R_{1} \longrightarrow CH \longrightarrow C \longrightarrow CH \longrightarrow R_{2} \longrightarrow CH \longrightarrow R_{3}$$

$$(II)$$

wherein R, R_1 , R_3 and are, independently, unsubstituted or substituted straight-chained, branched, or cyclic alkyl radicals C_1 - C_8 , or unsubstituted or substituted aryl radicals; and R_2 is a straight chain or branched C_1 to C_{16} alkyl group or a straight chain or branched C_1 to C_{16} alkyl group containing an ether group.

- 4. (Original) The article of Claim 1, wherein the diketene acetal is selected from a group consisting of 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane, 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane, 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane, 3,9-dipropylidene-2,4,8,10-tetraoxaspiro-[5,5]-tridecane, and mixtures thereof.
 - 5. Cancelled.
- 6. (Previously amended) The article of Claim 1, wherein the aliphatic diols comprise alkylene glycols or oligoalkylene glycols.
- 7. (Previously amended) The article of Claim 6, wherein the alkylene glycols are selected from a group consisting of ethylene glycol, 1,2-propylene glycol, 1,4-butanediol, 1,5-

pentanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, 1,12-dodecanediol, 1,13-tridecanediol, 1,14-tetradecanediol, 1,15-pentadecanediol, 1,16-hexadecanediol, 1,3-propylene glycol, butane-1,3-diol, pentane-2,4-diol, hexane-2,5-diol, and mixtures thereof.

- 8. (Previously amended) The article of Claim 6, wherein the oligoalkylene glycols are selected from a group consisting of poly(tetramethylene glycol), diethylene glycol, triethylene glycol, tetraethylene glycol, poly(tetraethylene glycol), poly(pentaethylene glycol), poly(hexamethylene glycol), poly(propylene glycol), and mixtures thereof.
- 9. (Previously amended) The article of Claim1, wherein the cycloaliphatic diols are selected from a group consisting of *trans*-cyclohexanedimethanol, *cis*-cyclohexanedimethanol, 1,2-cyclobutanediol, 1,3-cyclobutanediol, 1,2-cyclopentanediol, 1,3-cyclopentanediol, 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2-cycloheptanediol, 1,3-cycloheptanediol, 1,4-cycloheptanediol, and mixtures thereof.
- 10. (Previously amended) The article of Claim 1, wherein the aromatic diols are selected from a group consisting of *p* benzenedimethanol, *o* benzenedimethanol, *m*-benzenedimethanol, and mixtures thereof.
- 11. (Currently amended) The article of Claim1, The article of Claim 5, wherein the organosilicon diol is a carbinol-terminated poly(dimethyl siloxane).
- 12. (Original) The article of Claim 1, wherein a hydroxylated functional compound is additionally included in the polycondensation process.
- 13. (Original) The article of Claim 12, wherein the hydroxylated functional compound comprises poly(alkylene glycols), hydroxylated poly(N-vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, derivatives of hyaluronic acid, poly(2-hydroxyethyl methacrylate),

Docket Number: 50623.267

Express Mail Label No: EV 337975247 US

hydroxy functional poly(styrene sulfonate), hydroxy functional phosphoryl choline methacrylate polymers, polymers with both hydroxyl and phosphoryl choline functionality, heparin, or mixtures thereof.

- 14. (Original) The article of Claim 13, wherein the poly(alkylene glycols) are selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), and poly(ethylene oxide-co-propylene oxide).
- 15. (Currently amended) A medical device, comprising a coating, the coating comprising a polymer including a unit having a formula:

HO
$$R_3$$
 O CH_2 CH_2 O CH_2 CH_2 O CH_2 CH_2

wherein:

R and R₁ are, independently, unsubstituted or substituted straight-chained, branched, or cyclic alkyl radicals C₁-C₈, or unsubstituted or substituted aryl radicals;

R₃ is an aliphatic, cycloaliphatic, aromatic, or organosilicon group; and

"w" and "z" are integers, where the value of "w" is between 1 and 40, the value of "z" is between 9 and 700,

wherein the aliphatic diols comprises is derived from alkylene glycols, poly- or oligoalkylene glycols, or mixtures thereof; and

wherein the alkylene glycols are selected from the group consisting of ethylene glycol, 1,2-propylene glycol, 1,4-butanediol, 1,5-pentanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, 1,12-dodecanediol, 1,13-tridecanediol, 1,14-

Express Mail Label No: EV 337975247 US

tetradecanediol, 1,15-pentadecanediol, 1,16-hexadecanediol, 1,3-propylene glycol, butane-1,3-diol, pentane-2,4-diol, hexane-2,5-diol, and mixtures thereof.

- 16. (Original) The device of Claim 15, wherein the aliphatic radicals are selected from a group consisting of *n*-butyl and *n*-hexyl.
- 17. (Original) The device of Claim 15, wherein the cycloaliphatic radicals are selected from a group consisting of *trans*-cyclohexyl and *cis*-cyclohexyl.
- 18. (Currently amended) A medical device, comprising a coating, the coating comprising a polymer including a unit having a formula:

HO
$$R_3$$
 O CH_2 C

wherein:

R and R_1 are, independently, unsubstituted or substituted straight-chained, branched, or cyclic alkyl radicals C_1 - C_8 , or unsubstituted or substituted aryl radicals;

R₃ is an aliphatic, cycloaliphatic, aromatic, or organosilicon group; and

"w" and "z" are integers, where the value of "w" is between 1 and 40, the value of "z" is between 9 and 700, and

a polymer having a formula

$$HO = \begin{bmatrix} R_2 - O \end{bmatrix}_{\substack{\text{m} \\ \text{CH}_2}} O - CH_2 & CH_2 - O & CH_2 - O & CH_2 \\ CH_2 & O - CH_2 & CH_2 - O & CH_2 \\ R_1 & R_1 & R_2 & CH_2 - O & CH_2 \\ R_1 & R_2 & R_1 & R_2 & R_3 & R_4 \end{bmatrix}_{\substack{\text{q} \\ \text{q}}} O - CH_2 & CH_2 - O & CH_2 & CH_2 - O & CH_2 \\ R_1 & R_2 & R_3 & R_4 & R_4 & R_4 & R_4 & R_4 & R_4 \\ R_2 & O - CH_2 & CH_2 - O & CH_2 & CH_2 - O & CH_2 & CH_2 - O & CH_2 \\ R_1 & R_2 & CH_2 & CH_2 - O & CH_2 & CH_2 & CH_2 - O & CH_2 & CH_2$$

wherein:

R and R_1 are, independently, unsubstituted or substituted straight-chained, branched, or cyclic alkyl radicals C_1 - C_8 , or unsubstituted or substituted aryl radicals;

R₂-O is a non-fouling moiety derived from a hydroxylated functional compound;
R₃ is an aliphatic or cycloaliphatic group;

"m," "n," "p," and "q" are all integers, where the value of "m" is between 5 and 500, the value of "n" is between 2 and 350, the value of "p" is between 1 and 20, and the value of "q" is between 10 and 550.

- 19. (Original) The device of Claim 18, wherein the hydroxylated functional compound comprises poly(alkylene glycols), hydroxylated poly(N-vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, derivatives of hyaluronic acid, poly(2-hydroxyethyl methacrylate), hydroxy functional poly(styrene sulfonate), hydroxy functional phosphoryl choline methacrylate polymers, polymers with both hydroxyl and phosphoryl choline functionality, heparin, or mixtures thereof.
- 20. (Original) The device of Claim 19, wherein poly(alkylene glycols) are selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), and poly(ethylene oxide-co-propylene oxide).
- 21. (Previously amended) A method for fabricating a coating for an implantable medical device, the method comprising applying a polymer onto the surface of the device, wherein the polymer comprises a product of co-polycondensation of a diketene acetal and a diol,

wherein the diol comprises aliphatic, cycloaliphatic, aromatic, or organosilicon diols or combinations thereof,

wherein the aliphatic diols comprises alkylene glycols, poly- or oligoalkylene glycols, or mixtures thereof, and

wherein the alkylene glycols are selected from the group consisting of ethylene glycol, 1,2-propylene glycol, 1,4-butanediol, 1,5-pentanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, 1,12-dodecanediol, 1,13-tridecanediol, 1,14-tetradecanediol, 1,15-pentadecanediol, 1,16-hexadecanediol, 1,3-propylene glycol, butane-1,3-diol, pentane-2,4-diol, hexane-2,5-diol, and mixtures thereof.

- 22. (Original) The method of Claim 21, wherein the medical device is a stent.
- 23. (Previously amended) The method of Claim 21, wherein the diketene acetal is selected from a group of compounds having formulae (I) and (II):

$$R - CH = C - CH_{2}C - CH_{2} - O - CH_{2}C - CH_{2} - CH_{2} - CH_{2} - CH_{2} - CH_{2}C - CH_{2} - CH_{2}C - CH_{2$$

wherein R, R_1 , R_3 and are, independently, <u>unsubstituted</u> or substituted straight-chained, branched, or cyclic alkyl radicals C_1 - C_8 , or <u>unsubstituted</u> or substituted aryl radicals; and R_2 is a straight chain or branched C_1 to C_{16} alkyl group or a straight chain or branched C_1 to C_{16} alkyl group containing an ether group.

- 24. (Original) The method of Claim 21, wherein the diketene acetal is selected from a group consisting of 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane, 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane, 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane, 3,9-dipropylidene-2,4,8,10-tetraoxaspiro-[5,5]-tridecane, and mixtures thereof.
 - 25. Cancelled.

26. (Previously amended) The method of Claim 21, wherein the aliphatic diols comprise alkylene glycols or oligoalkylene glycols.

- 27. (Previously amended) The method of Claim 26, wherein the alkylene glycols are selected from a group consisting of ethylene glycol, 1,2-propylene glycol, 1,4-butanediol, 1,5-pentanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, 1,12-dodecanediol, 1,13-tridecanediol, 1,14-tetradecanediol, 1,15-pentadecanediol, 1,16-hexadecanediol, 1,3-propylene glycol, butane-1,3-diol, pentane-2,4-diol, hexane-2,5-diol, and mixtures thereof.
- 28. (Previously amended) The method of Claim 26, wherein the oligoalkylene glycols are selected from a group consisting of poly(tetramethylene glycol), diethylene glycol, triethylene glycol, tetraethylene glycol, poly(tetraethylene glycol), poly(pentaethylene glycol), poly(hexamethylene glycol), poly(propylene glycol), and mixtures thereof.
- 29. (Original) The method of Claim 25, wherein the cycloaliphatic diols are selected from a group consisting of *trans*-cyclohexanedimethanol, *cis*-cyclohexanedimethanol, 1,2-cyclobutanediol, 1,3-cyclobutanediol, 1,2-cyclopentanediol, 1,3-cyclohexanediol, 1,2-cyclohexanediol, 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2-cycloheptanediol, 1,3-cycloheptanediol, 1,4-cycloheptanediol, and mixtures thereof.
- 30. (Original) The method of Claim 25, wherein the aromatic diols are selected from a group consisting of *p*-benzenedimethanol, *o*-benzenedimethanol, *m*-benzenedimethanol, and mixtures thereof.
- 31. (Original) The method of Claim 25, wherein the organosilicon diol is a carbinol-terminated poly(dimethyl siloxane).

32. (Original) The method of Claim 21, wherein a hydroxylated functional compound is additionally included in the polycondensation process.

- 33. (Original) The method of Claim 32, wherein the hydroxylated functional compound comprises poly(alkylene glycols), hydroxylated poly(N-vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, derivatives of hyaluronic acid, poly(2-hydroxyethyl methacrylate), hydroxy functional poly(styrene sulfonate), hydroxy functional phosphoryl choline methacrylate polymers, polymers with both hydroxyl and phosphoryl choline functionality, heparin, or mixtures thereof.
- 34. (Original) The method of Claim 33, wherein the poly(alkylene glycols) are selected from a group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), and poly(ethylene oxide-co-propylene oxide).
- 35. (Previously presented) The article of claim 1, wherein the diol comprises an aliphatic diol.
- 36. (Previously presented) The article of claim 1, wherein the diol comprises a cycloaliphatic diol.
- 37. (Previously presented) The article of claim 1, wherein the diol comprises an aromatic diol.
- 38. (Previously presented) The article of claim 1, wherein the diol comprises an organosilicon diol.
- 39. (Previously presented) The article of claim 1, wherein the diketene acetal comprises 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane.
- 40. (Previously presented) The article of claim 1, wherein the diketene acetal comprises 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane.

10

41. (Previously presented) The article of claim 1, wherein the diketene acetal comprises 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane.

- 42. (Previously presented) The article of claim 1, wherein the diketene acetal comprises 3,9-dipropylidene-2,4,8,10-tetraoxaspiro-[5,5]-tridecane.
- 43. (Previously presented) The article of claim 12, wherein the hydroxylated functional compound comprises poly(alkylene glycols).
- 44. (Currently amended) A medical article, comprising an implantable substrate having a coating deposited on the substrate, the coating comprising a polymer, the polymer being a product of co-polycondensation of a diketene acetal, a diol and a hydroxylated functional,

wherein the diol comprises aliphatic, cycloaliphatic, aromatic, or organosilicon diols or combinations thereof,

wherein the aliphatic diol comprises alkylene glycols, poly- or oligoalkylene glycols, or mixtures thereof,

wherein the alkylene glycols are selected from the group consisting of ethylene glycol, 1,2-propylene glycol, 1,4-butanediol, 1,5-pentanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-undecanediol, 1,12-dodecanediol, 1,13-tridecanediol, 1,14-tetradecanediol, 1,15-pentadecanediol, 1,16-hexadecanediol, 1,3-propylene glycol, butane-1,3-diol, pentane-2,4-diol, hexane-2,5-diol, and mixtures thereof,

The article of claim 12, wherein the hydroxylated functional compound comprises any of hydroxylated poly(N-vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, derivatives of hyaluronic acid, poly(2-hydroxyethyl methacrylate), hydroxy functional poly(styrene sulfonate), hydroxy functional phosphoryl choline methacrylate polymers, polymers with both hydroxyl and phosphoryl choline functionalities, heparin or combinations thereof.

11

45-53. Cancelled.

54. (Previously presented) The article of claim 1, wherein the diol comprises ethylene glycol.

- 55. (Previously presented) The article of claim 1, wherein the diol comprises 1,2-propylene glycol.
- 56. (Previously presented) The article of claim 1, wherein the diol comprises 1,4-butanediol.
- 57. (Previously presented) The article of claim 1, wherein the diol comprises 1,5-pentanediol.
- 58. (Previously presented) The article of claim 1, wherein the diol comprises 1,7-heptanediol.
- 59. (Previously presented) The article of claim 1, wherein the diol comprises 1,8-octanediol.
- 60. (Previously presented) The article of claim 1, wherein the diol comprises 1,9-nonanediol.
- 61. (Previously presented) The article of claim 1, wherein the diol comprises 1,10-decanediol.
- 62. (Previously presented) The article of claim 1, wherein the diol comprises 1,11-undecanediol.
- 63. (Previously presented) The article of claim 1, wherein the diol comprises 1,12-dodecanediol.
- 64. (Previously presented) The article of claim 1, wherein the diol comprises 1,13-tridecanediol.

SanFrancisco/144416.1 12

65. (Previously presented) The article of claim 1, wherein the diol comprises 1,14-tetradecanediol.

- 66. (Previously presented) The article of claim 1, wherein the diol comprises 1,15-pentadecanediol.
- 67. (Previously presented) The article of claim 1, wherein the diol comprises 1,16-hexadecanediol.
- 68. (Previously presented) The article of claim 1, wherein the diol comprises 1,3-propylene glycol.
- 69. (Previously presented) The article of claim 1, wherein the diol comprises butane-1,3-diol.
- 70. (Previously presented) The article of claim 1, wherein the diol comprises pentane-2,4-diol.
- 71. (Previously presented) The article of claim 1, wherein the diol comprises hexane-2,5-diol.
- 72. (Previously presented) The article of claim 1, wherein the diol comprises poly(tetramethylene glycol).
- 73. (Previously presented) The article of claim 1, wherein the diol comprises diethylene glycol.
- 74. (Previously presented) The article of claim 1, wherein the diol comprises triethylene glycol.
- 75. (Previously presented) The article of claim 1, wherein the diol comprises tetraethylene glycol.

76. (Previously presented) The article of claim 1, wherein the diol comprises poly(tetraethylene glycol).

- 77. (Previously presented) The article of claim 1, wherein the diol comprises poly(pentaethylene glycol).
- 78. (Previously presented) The article of claim 1, wherein the diol comprises poly(hexamethylene glycol).
- 79. (Previously presented) The article of claim 1, wherein the diol comprises poly(propylene glycol).
- 80. (Previously presented) The article of claim 1, wherein the diol comprises *trans*-cyclohexanedimethanol.
- 81. (Previously presented) The article of claim 1, wherein the diol comprises *cis*-cyclohexanedimethanol.
- 82. (Previously presented) The article of claim 1, wherein the diol comprises 1,2-cyclobutanediol,
- 83. (Previously presented) The article of claim 1, wherein the diol comprises 1,3-cyclobutanediol.
- 84. (Previously presented) The article of claim 1, wherein the diol comprises 1,2-cyclopentanediol.
- 85. (Previously presented) The article of claim 1, wherein the diol comprises 1,3-cyclopentanediol.
- 86. (Previously presented) The article of claim 1, wherein the diol comprises 1,2-cyclohexanediol.

87. (Previously presented) The article of claim 1, wherein the diol comprises 1,3-cyclohexanediol.

- 88. (Previously presented) The article of claim 1, wherein the diol comprises 1,4-cyclohexanediol.
- 89. (Previously presented) The article of claim 1, wherein the diol comprises 1,2-cycloheptanediol.
- 90. (Previously presented) The article of claim 1, wherein the diol comprises 1,3-cycloheptanediol.
- 91. (Previously presented) The article of claim 1, wherein the diol comprises 1,4-cycloheptanediol.
- 92. (Previously presented) The article of claim 1, wherein the diol comprises caprolactone diol.
- 93. (Previously presented) The article of claim 1, wherein the diol comprises *p*-benzenedimethanol.
- 94. (Previously presented) The article of claim 1, wherein the diol comprises *o*-benzenedimethanol.
- 95. (Previously presented) The article of claim 1, wherein the diol comprises *m*-benzenedimethanol.
- 96. (Previously presented) The article of claim 1, wherein the diol comprises a carbinol-terminated poly(dimethyl siloxane).
- 97. (Previously presented) A medical article, comprising an implantable substrate having a coating deposited on the substrate, the coating comprising a polymer, the polymer being a product of co-polycondensation of a diketene acetal and a diol,

wherein the diol comprises aliphatic, cycloaliphatic, aromatic, or organosilicon diols or combinations thereof, and

wherein the cycloaliphatic diol is selected from a group consisting of *cis*-cyclohexanedimethanol, 1,2-cyclobutanediol, 1,3-cyclobutanediol, 1,2-cyclopentanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,2-cyclohexanediol, 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,3-cycloheptanediol, 1,3-cycloheptanediol, caprolactone diol, and mixtures thereof.

- 98. (Previously presented) A medical article, comprising an implantable substrate having a coating deposited on the substrate, the coating comprising a polymer, the polymer being a product of co-polycondensation of a diketene acetal and a diol, wherein the diketene acetal is selected from the group consisting of 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane, 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane, 3,9-dipropylidene-2,4,8,10-tetraoxaspiro-[5,5]-tridecane, and mixtures thereof.
- 99. (Currently amended) A medical device comprising a coating which comprises a polymer including a unit having a formula:

HO
$$\begin{array}{c|c}
\hline
 R_3 - O \\
\hline
 CH_2 \\
 CH_2
\end{array}$$

$$\begin{array}{c|c}
 CH_2 - O \\
 CH_2
\end{array}$$

$$\begin{array}{c|c}
 CH_2 - O \\
 CH_2
\end{array}$$

$$\begin{array}{c|c}
 CH_2 \\
 R_1
\end{array}$$

wherein:

R and R_1 are, independently, unsubstituted or substituted straight-chained, branched, or cyclic alkyl radicals C_1 - C_8 , or unsubstituted or substituted aryl radicals;

R₃ is an aliphatic, cycloaliphatic, aromatic, or organosilicon group; and

Docket Number: 50623.267

Express Mail Label No: EV 337975247 US

"w" and "z" are integers, where the value of "w" is between 1 and 40, the value of "z" is between 9 and 700, and

wherein the cycloaliphatic diol group is derived from a diol selected from a group consisting of *cis*-cyclohexanedimethanol, 1,2-cyclobutanediol, 1,3-cyclobutanediol, 1,2-cyclohexanediol, 1,3-cyclohexanediol, 1,4-cyclohexanediol, 1,4-cyclohexanediol, 1,2-cycloheptanediol, 1,3-cycloheptanediol, 1,4-cycloheptanediol, caprolactone diol, and mixtures thereof.